Conclusion of an agreement for the acquisition without payment of own shares by the Company for the purpose of implementing an incentive programme

Current report no. 30/2025

Date of preparation: 7 August 2025

Subject: Conclusion of an agreement for the acquisition without payment of own shares by the Company for the purpose of implementing an incentive programme

Legal basis: Article 17(1) of the MAR Regulation – confidential information

Content of the report:

The Management Board of Captor Therapeutics S.A. with its registered office in Wrocław (the “Company”) hereby announces that today, i.e. 7 August 2025, an agreement was concluded for the acquisition without payment of 20,000 shares in the Company (hereinafter referred to as the “Shares” and the “Agreement”) between the Company (as the purchaser) and Michał Walczak, President of the Management Board of the Company (as the seller) (“Seller”).

The acquisition of the Shares constitutes the exercise of the right granted to the Company on the basis of resolutions of the Company's General Meeting, i.e. Resolution No. 4 of the Extraordinary General Meeting of the Company of 24 February 2025 and Resolution No. 21 of the Ordinary General Meeting of the Company of 26 June 2025, which the Company announced in current report No. 15/2025 of 24 February 2025 and current report No. 27/2025 of 26 June 2025, respectively.

Pursuant to the above-mentioned resolutions, consent was given for the Company to acquire, free of charge, a total of up to 20,000 own shares from the Seller for use in the incentive programme established by the Company.

The transfer of the Shares to the Company will be effected by way of settlement of brokerage instructions outside the regulated market, through brokerage houses.

The Agreement also provides for a mechanism for the return of Shares to the Seller if they are not used under the incentive programme within a specified period. In particular, if the Shares are not transferred to the programme participants within 5 years from the date of conclusion of the Agreement, it is possible to return them free of charge to the Seller on the basis of a separate transfer agreement in accordance with the above-mentioned resolutions of the General Meeting, which are the basis for the acquisition of own shares by the Company.

The acquired Shares represent approximately 0.36% of the Company's share capital and approximately 0.30% of the total number of votes at the Company's General Meeting. Pursuant to Article 364 § 2 of the Commercial Companies Code, the Company does not exercise voting rights attached to its own shares.

Apart from the above-mentioned 20,000 shares, the Company does not hold any other own shares.